long intergenic non-protein coding RNA 1423Genealiases: []
Q-omics provides the consensus-scored LINC01423 profile across patient tissues and cancer cell-line models. LINC01423 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LINC01423 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, LINC01423 RNA expression shows 9,050 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUAD, THCA, and LAML as cancer lineages where LINC01423 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01423 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01423 survival associations across molecular data types. LINC01423 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01423 RNA expression–survival associations across cancer types. High LINC01423 expression shows unfavorable associations in UVM, STAD, BRCA, ACC and GBM, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LINC01423 RNA expression.
This table summarizes LINC01423 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01423. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01423 shows lower tumor expression in THCA, KICH, LUSC, KIRP and KIRC and higher tumor expression in PRAD. The THCA box plot shows higher LINC01423 RNA expression in normal versus tumor tissue (log2 FC = −2.020, t-test p < 0.001).
This table shows molecular features associated with LINC01423 in patient tissues and cancer cell lines. In patient samples, LINC01423 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
